Union Bancaire Privee UBP SA Takes Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Union Bancaire Privee UBP SA bought a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 20,000 shares of the company's stock, valued at approximately $446,000.

Several other hedge funds have also recently made changes to their positions in TEVA. UMB Bank n.a. increased its holdings in shares of Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company's stock valued at $44,000 after purchasing an additional 2,067 shares during the period. Smithfield Trust Co raised its position in Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock worth $50,000 after buying an additional 980 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at $50,000. Claro Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the third quarter worth $52,000. Finally, Venturi Wealth Management LLC purchased a new position in shares of Teva Pharmaceutical Industries during the third quarter worth $60,000. 54.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Roberto Mignone sold 286,000 shares of the business's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares in the company, valued at $15,296,950. This trade represents a 29.15 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock traded down $2.93 during trading on Wednesday, reaching $18.60. The company had a trading volume of 41,908,446 shares, compared to its average volume of 11,409,515. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The firm's 50-day simple moving average is $19.94 and its 200 day simple moving average is $18.47. The firm has a market capitalization of $21.08 billion, a PE ratio of -21.89, a price-to-earnings-growth ratio of 1.11 and a beta of 0.73. Teva Pharmaceutical Industries Limited has a 1-year low of $11.48 and a 1-year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 5.73% and a positive return on equity of 42.92%. As a group, equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.37 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TEVA has been the topic of several analyst reports. Barclays increased their price target on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 18th. Piper Sandler raised their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. StockNews.com downgraded Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a report on Wednesday, December 18th. JPMorgan Chase & Co. raised their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, October 21st. Finally, UBS Group lifted their target price on shares of Teva Pharmaceutical Industries from $28.00 to $30.00 and gave the company a "buy" rating in a report on Thursday, January 23rd. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of "Moderate Buy" and an average target price of $22.63.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.